Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (4 quarters reported)
$104M in Q4 2021 → — now. Hover for any quarter.
As reported for the quarter ended September 30, 2022. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Abcellera Biologics, Inc. | NaN% | Trimmed 100% | 0 | — |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 3 quarters.
quarter ended September 30, 2022 · filed November 14, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Abcellera Biologics, Inc. | Trimmed | −29,411 | — | — |
quarter ended June 30, 2022 · filed November 14, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Abcellera Biologics, Inc. | Trimmed | −7,276,350 | −$77.4M | 100.0% |
quarter ended March 31, 2022 · filed November 14, 2022
No position changes this quarter.
Loading...
